Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Alan Fogleman
University of California Los Angeles, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Bruin Pharma
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution
Investigator is the head of the study. He is the inventor of IP and has equity interest.
Targeting the Enterocyte to Prevent Vascular Inflammation
Project Narrative We discovered that lipid signaling molecules produced in small intestine absorptive cells amplify the ability of dietary fat to cause dyslipidemia, atherosclerosis and vascular inflammation. We developed an oral concentrate of tomatoes containing a mimetic of the main protein in HDL that decreases the levels of these signaling molecules, and ameliorates dyslipidemia, atherosclerosis and vascular inflammation in mice fed a high-fat high-cholesterol diet. The proposed studies are aimed at understanding the mechanisms by which the lipid signaling molecules amplify the effects of dietary fat, and the mechanisms by which the oral concentrate ameliorates the effects of these lipid signaling molecules.
Filed on June 21, 2019.
Tell us what you know about Alan Fogleman's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Alan Fogleman”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Alan Fogleman | University of California Los Angeles | Conflict of Interest | Bruin Pharma | $450,000 - $499,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.